56 related articles for article (PubMed ID: 38721105)
41. Current situation of viral hepatitis in Egypt.
Elbahrawy A; Ibrahim MK; Eliwa A; Alboraie M; Madian A; Aly HH
Microbiol Immunol; 2021 Sep; 65(9):352-372. PubMed ID: 33990999
[TBL] [Abstract][Full Text] [Related]
42. Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes.
Ito T; Nguyen MH
J Hepatocell Carcinoma; 2023; 10():413-428. PubMed ID: 36926055
[TBL] [Abstract][Full Text] [Related]
43. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review.
Alavian SM; Haghbin H
Hepat Mon; 2016 Mar; 16(3):e35106. PubMed ID: 27226803
[TBL] [Abstract][Full Text] [Related]
44. MAFLD: an optimal framework for understanding liver cancer phenotypes.
Crane H; Gofton C; Sharma A; George J
J Gastroenterol; 2023 Oct; 58(10):947-964. PubMed ID: 37470858
[TBL] [Abstract][Full Text] [Related]
45. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective.
Fouad Y; Lazarus JV; Negro F; Peck-Radosavljevic M; Sarin SK; Ferenci P; Esmat G; Ghazinian H; Nakajima A; Silva M; Lee S; Colombo M
Aliment Pharmacol Ther; 2021 May; 53(10):1080-1089. PubMed ID: 33751604
[TBL] [Abstract][Full Text] [Related]
46. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.
Kawaguchi T; Tsutsumi T; Nakano D; Eslam M; George J; Torimura T
Clin Mol Hepatol; 2022 Apr; 28(2):150-163. PubMed ID: 34753279
[TBL] [Abstract][Full Text] [Related]
47. Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis.
Wang X; Xie Q
J Clin Transl Hepatol; 2022 Feb; 10(1):128-133. PubMed ID: 35233381
[TBL] [Abstract][Full Text] [Related]
48. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
Fassio E; Barreyro FJ; Pérez MS; Dávila D; Landeira G; Gualano G; Ruffillo G
World J Hepatol; 2022 Feb; 14(2):354-371. PubMed ID: 35317172
[TBL] [Abstract][Full Text] [Related]
49. Risk factors for hepatocellular carcinoma in India.
Kar P
J Clin Exp Hepatol; 2014 Aug; 4(Suppl 3):S34-42. PubMed ID: 25755609
[TBL] [Abstract][Full Text] [Related]
50. Insight into the regulatory mechanism of m
Zha X; Gao Z; Li M; Xia X; Mao Z; Wang S
Biomed Pharmacother; 2024 Jun; 177():116966. PubMed ID: 38906018
[TBL] [Abstract][Full Text] [Related]
51. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.
Karin M; Kim JY
Mol Oncol; 2024 Jun; ():. PubMed ID: 38874196
[TBL] [Abstract][Full Text] [Related]
52. Changes in the Etiologies of Liver Cancer in Upper Egypt over a Decade from 2010 to 2020: A Single Tertiary Care Center Study.
Fouad Y; Gaber Y; Alem SA; Abdallah M; Abd-Elsalam SM; Nafady S; Attia D; Eslam M
South Asian J Cancer; 2024 Jan; 13(1):10-16. PubMed ID: 38721105
[TBL] [Abstract][Full Text] [Related]
53. Should we undertake surveillance for HCC in patients with MAFLD?
Norero B; Dufour JF
Ther Adv Endocrinol Metab; 2023; 14():20420188231160389. PubMed ID: 37006779
[TBL] [Abstract][Full Text] [Related]
54. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention.
Anwar WA; Khaled HM; Amra HA; El-Nezami H; Loffredo CA
Mutat Res; 2008; 659(1-2):176-84. PubMed ID: 18346933
[TBL] [Abstract][Full Text] [Related]
55. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures.
Ezzat R; Eltabbakh M; El Kassas M
World J Gastrointest Oncol; 2021 Dec; 13(12):1919-1938. PubMed ID: 35070033
[TBL] [Abstract][Full Text] [Related]
56. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis.
Lehman EM; Wilson ML
Int J Cancer; 2009 Feb; 124(3):690-7. PubMed ID: 18973270
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
